CAF-Encapsulated Pancreatic Beta Cells for Diabetes

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for diabetes, particularly type 1, face challenges due to immune system rejection of transplanted pancreatic islets, leading to short-term efficacy and the need for long-term, economical solutions for insulin production.

Innovation Solution

Encapsulation of insulin-producing cells using cancer-associated fibroblasts (CAFs), fibroblasts, and their secreted extracellular matrix (ECM) to protect cells from immune attack and promote blood vessel formation, enabling stable insulin production.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If pancreatic islets are transplanted to treat diabetes, then insulin production is restored, but the immune system destroys the transplanted islets

Engineering Contradiction:

Improveinsulin production stabilityVSAvoidimmune system rejection

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

Cancer-associated fibroblasts (CAFs) serve as an intermediary protective layer between the transplanted pancreatic islets and the host immune system. The CAFs form a capsule around the islets, physically blocking immune cells and antibodies from accessing and destroying the insulin-producing beta cells, thereby protecting the transplanted tissue while maintaining its function

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The pancreatic islets are nested within a capsule formed by cancer-associated fibroblasts. This nested structure allows the islets to be protected inside the CAF capsule, which itself is protected by the host tissue. The nested arrangement provides multiple layers of protection against immune rejection while maintaining nutrient and hormone exchange

Inventive Principle:

Principle #7Nested doll (Nesting)

2Duration of action of stationary object

If pancreatic islets are transplanted without protection, then initial insulin production occurs, but long-term persistence is prevented by immune rejection

Engineering Contradiction:

Improvetransplanted islet persistenceVSAvoidlong-term insulin production

Core Design Contradiction:

Duration of action of stationary objectVSReliability

Solution Approach 1:

Cancer-associated fibroblasts are pre-differentiated and pre-assembled into a protective capsule structure before the pancreatic islets are transplanted. This preliminary preparation ensures that the protective barrier is already in place to immediately protect the islets upon transplantation, preventing early immune rejection and establishing long-term persistence

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The CAF capsule acts as a pre-established protective cushion between the vulnerable transplanted islets and the hostile immune environment. This beforehand cushioning prevents immune cells from directly contacting and destroying the islets, ensuring long-term survival and continuous insulin production

Inventive Principle:

Principle #11Beforehand cushioning (Prior cushioning)

Data Source

PatentUS20250090595A1Therapeutic use of cancer-associated fibroblast-encapsulated pancreatic beta cells for treating diabetes

Publication Date: 2025.03.20 FIBROBIOLOGICS INC

AI summary

Disclosed herein are compositions comprising one or more cell types encapsulated by a plurality of cancer-associated fibroblasts (CAFs) and/or fibroblasts; and/or one or more cell types encapsulated by extracellular matrix (ECM) secreted by CAFs and/or fibroblasts. Also disclosed are methods for producing compositions disclosed herein, methods of using compositions disclosed herein for treatment of diseases and/or disorders, and kits for practicing the methods disclosed herein.